SCHEMBL5332737

SCHEMBL5332737

Cn1cc(-c2cc(Oc3cc(N)c(F)cc3F)ncn2)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
CSF1R P07333 4/20 0.36
KDR P35968 1/20 0.35
PIM1 P11309 5/20 0.35
FGFR1 P11362 4/20 0.35
FGFR2 P21802 4/20 0.35
FGFR3 P22607 4/20 0.35
MET P08581 2/20 0.35
FGFR4 P22455 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CG P48736 1/20 0.34
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT3 P36888 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336667 0.83 ABL1 (0.46) ABL1BCRALOX5APFEN1CSF1R
SCHEMBL5428776 0.83 ABL1 (0.46) ABL1BCRALOX5APFEN1CSF1R
SCHEMBL5335338 0.77 MET (0.36) ALOX5APFEN1METPIK3CDPIK3CA
SCHEMBL3492778 0.76 CSF1R (0.51) CSF1RKDRMETPDGFRBPDGFRA
SCHEMBL29736569 0.76 CSF1R (0.51) CSF1RKDRMETPDGFRBPDGFRA
SCHEMBL5335592 0.76 ABL1 (0.47) ABL1BCRCSF1RKDRPIM1
SCHEMBL5426547 0.75 PIM1 (0.44) ABL1BCRALOX5APFEN1CSF1R
SCHEMBL14447155 0.74 ABL1 (0.47) ABL1BCRCSF1RPIM1FGFR1
SCHEMBL24920790 0.74 MAPT (0.51) ABL1BCRKDRPIM1FGFR1
SCHEMBL24196292 0.74 PIM1 (0.51) ALOX5APFEN1KDRPIM1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 ABL1 47/4885BCR 88/4885ALOX5AP 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.